Literature DB >> 23267166

Second primary cancer in patients with papillary thyroid carcinoma.

Carles Zafon1, Gabriel Obiols, Jordi Mesa.   

Abstract

BACKGROUND AND AIM: There is an increased incidence of secondary primary cancer (SPC) in patients with papillary thyroid carcinoma (PTC). The risk is stronger in the first year after the first malignancy (synchronous tumours). The aim of this study was to assess the prevalence of SPC in patients with PTC, and to analyse whether the timing of tumour presentation influenced the clinicopathological characteristics of PTC. PATIENTS AND METHODS: A total of 184 patients with PTC were included in the study.
RESULTS: There were 24 patients with SPC and nine with PTC and two other primary tumours (42 additional malignancies in total). Additional tumours were more prevalent in male and older patients. In 11 cases (33%), the two carcinomas were synchronous. PTCs from synchronous cases were significantly larger than those from non-synchronous cases.
CONCLUSION: Patients with PTC were at elevated risk for SPC. In one third of patients, both neoplasms were diagnosed within the same year. Male and older patients were more likely to have SPC.

Entities:  

Mesh:

Year:  2013        PMID: 23267166

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Risk of Second Primary Thyroid Cancer in Women with Breast Cancer.

Authors:  Monika Cieszyńska; Wojciech Kluźniak; Dominika Wokołorczyk; Cezary Cybulski; Tomasz Huzarski; Jacek Gronwald; Michał Falco; Tadeusz Dębniak; Anna Jakubowska; Róża Derkacz; Wojciech Marciniak; Marcin Lener; Karolina Woronko; Dominika Mocarz; Piotr Baszuk; Marta Bryśkiewicz; Steven A Narod; Jan Lubiński
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

2.  Incidental discovery of a Hodgkin lymphoma synchronous to a papillary thyroid carcinoma.

Authors:  Maissa Ben Thayer; Fatma Khanchel; Imen Helal; Dorra Chiboub; Khouloud Ben Lazreg; Raweh Hedhli; Ehsen Ben Brahim; Raja Jouini; Aschraf Cheddli-Debbich
Journal:  Clin Case Rep       Date:  2022-08-09

Review 3.  Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive-resistant differentiated thyroid cancer.

Authors:  Marcel Sambo
Journal:  Cancer Med       Date:  2022-10       Impact factor: 4.711

4.  Therapeutic Outcome of Second Primary Malignancies in Patients with Well-Differentiated Thyroid Cancer.

Authors:  Miaw-Jene Liou; Ngan-Ming Tsang; Chuen Hsueh; Tzu-Chieh Chao; Jen-Der Lin
Journal:  Int J Endocrinol       Date:  2016-03-29       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.